Management of ductal carcinoma in situ of the breast a review

JAMA Oncology

Volumn 2, Issue 8, 2016, Pages 1083-1088

  Shah, Chirag ^a   Wobb, Jessica ^b   Manyam, Bindu ^c   Kundu, Neilendu ^d   Arthur, Douglas ^d   Wazer, David ^e,f   Fernandez, Eduardo ^g   Vicini, Frank ^g  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BROWN UNIVERSITY   (United States)

^g 21ST CENTURY ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT RADIOTHERAPY; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EPIDEMIOLOGY; FEMALE; HUMAN; PARTIAL MASTECTOMY; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT;

EID: 85014960980     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.0525     Document Type: Review

References (52)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.
2. National Comprehensive Cancer Network. Survivorship. Version 2. 2015. http://www.nccn.org /professionals/physician-gls/pdf/breast.pdf. Requires login. Accessed December 29, 2015.
3. Solin LJ, Fourquet A, Vicini FA, et al. Long-Term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer. 2005;103 (6):1137-1146.
4. Stuart KE, Houssami N, Taylor R, Hayen A, Boyages J. Long-Term outcomes of ductal carcinoma in situ of the breast: A systematic review, meta-Analysis and meta-regression analysis. BMC Cancer. 2015;15:890.
5. Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 2015;1(7):888-896.
6. Esserman L, Yau C. Rethinking the standard for ductal carcinoma in situ treatment. JAMA Oncol. 2015;1(7):881-883.
7. Meyerson AF, Lessing JN, Itakura K, et al. Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. Breast. 2011;20(6):529-533.
8. Losken A, Hamdi M. Partial Breast Reconstruction: Techniques in Oncoplastic Surgery. Boca Raton, FL: CRC Press; 2009.
9. Spear SL, Hannan CM, Willey SC, Cocilovo C. Nipple-sparing mastectomy. Plast Reconstr Surg. 2009;123(6):1665-1673.
10. EmirogluM, Salimoglu S, Karaali C, et al. Oncoplastic reduction mammoplasty for breast cancer in women with macromastia: oncological long-Term outcomes [published online September 7, 2015]. Asian J Surg. 2015;S1015-9584(15)00092-5.
11. Peled AW, Sbitany H, Foster RD, Esserman LJ. Oncoplastic mammoplasty as a strategy for reducing reconstructive complications associated with postmastectomy radiation therapy. Breast J. 2014;20(3):302-307.
12. Bartelink H, Maingon P, Poortmans P, et al; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16 (1):47-56.
13. Omlin A, AmichettiM, Azria D, et al. Boost radiotherapy in young women with ductal carcinoma in situ: A multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol. 2006;7(8):652-656.
14. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227-1232.
15. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16): 1233-1241.
16. Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-Term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12 (1):21-29.
17. Wärnberg F, Garmo H, Emdin S, et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol. 2014;32 (32):3613-3618.
18. Wapnir IL, Dignam JJ, Fisher B, et al. Long-Term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478-488.
19. Donker M, Litière S, Werutsky G, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol. 2013;31(32):4054-4059.
20. Correa C, McGale P, Taylor C, et al; EarlyBreast Cancer Trialists' Collaborative Group (EBCTCG). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010(41):162-177.
21. Sagara Y, Freedman RA, Vaz-Luis I, et al. Patient prognostic score and associations with survival improvement offered by radiotherapy after breast-conserving surgery for ductal carcinoma in situ: A population-based longitudinal cohort study. J Clin Oncol. 2016;34(11):1190-1196.
22. Shaitelman SF, Wilkinson JB, Kestin LL, et al. Long-Term outcome in patients with ductal carcinoma in situ treated with breast-conserving therapy: implications for optimal follow-up strategies. Int J Radiat Oncol Biol Phys. 2012;83(3): e305-e312.
23. Wilkinson JB, Vicini FA, Shah C, et al. Twenty-year outcomes after breast-conserving surgery and definitive radiotherapy for mammographically detected ductal carcinoma in situ. Ann Surg Oncol. 2012;19(12):3785-3791.
24. Wong JS, Chen YH, Gadd MA, et al. Eight-year update of a prospective study of wide excision alone for small low-or intermediate-grade ductal carcinoma in situ (DCIS). Breast Cancer Res Treat. 2014;143(2):343-350.
25. Solin LJ, Gray R, Hughes LL, et al. Surgical excision without radiation for ductal carcinoma in situ of the breast:12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol. 2015;33 (33):3938-3944.
26. McCormick B. RTOG 9804: A prospective randomized trial for "good risk" ductal carcinoma in situ (DCIS), comparing radiation (RT) to observation (OBS). J Clin Oncol. 2012;30(suppl):A1004.
27. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701-710.
28. Rakovitch E, Nofech-Mozes S, HannaW, et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat. 2015;152(2):389-398.
29. Whelan TJ, Pignol JP, Levine MN, et al. Long-Term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362 (6):513-520.
30. Haviland JS, Owen JR, Dewar JA, et al; START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14 (11):1086-1094.
31. Lalani N, Paszat L, Sutradhar R, et al. Long-Term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys. 2014;90(5):1017-1024.
32. Smith BD, Bentzen SM, Correa CR, et al. Fractionation for whole breast irradiation: An American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;81(1):59-68.
33. Vicini FA, Kestin LL, Goldstein NS. Defining the clinical target volume for patients with early-stage breast cancer treated with lumpectomy and accelerated partial breast irradiation: A pathologic analysis. Int J Radiat Oncol Biol Phys. 2004;60(3): 722-730.
34. Strnad V, Ott OJ, Hildebrandt G, et al; Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: A randomised, phase 3, non-inferiority trial. Lancet. 2016;387(10015):229-238.
35. Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015;51(4):451-463.
36. Polgár C, Fodor J, Major T, Sulyok Z, Kásler M. Breast-conserving therapy with partial or whole breast irradiation: Ten-year results of the Budapest randomized trial. Radiother Oncol. 2013;108(2):197-202.
37. Rodrìguez N, Sanz X, Dengra J, et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2013;87(5): 1051-1057.
38. KamravaM, Kuske RR, Anderson B, et al. Outcomes of breast cancer patients treated with accelerated partial breast irradiation via multicatheter interstitial brachytherapy: The Pooled Registry of Multicatheter Interstitial Sites (PROMIS) experience. Ann Surg Oncol. 2015;22(suppl 3): S404-S411. doi:10.1245/s10434-015-4563-7.
39. Israel PZ, Vicini F, Robbins AB, et al. Ductal carcinoma in situ of the breast treated with accelerated partial breast irradiation using balloon-based brachytherapy. Ann Surg Oncol. 2010;17(11):2940-2944.
40. Shah C, McGee M, Wilkinson JB, et al. Clinical outcomes using accelerated partial breast irradiation in patients with ductal carcinoma in situ. Clin Breast Cancer. 2012;12(4):259-263.
41. Vicini F, Shah C, Ben Wilkinson J, Keisch M, Beitsch P, Lyden M. Should ductal carcinoma-in-situ (DCIS) be removed from the ASTRO consensus panel cautionary group for off-protocol use of accelerated partial breast irradiation (APBI)? a pooled analysis of outcomes for 300 patients with DCIS treated with APBI. Ann Surg Oncol. 2013;20 (4):1275-1281.
42. Shah C, Vicini F, Wazer DE, Arthur D, Patel RR. The American Brachytherapy Society consensus statement for accelerated partial breast irradiation. Brachytherapy. 2013;12(4):267-277.
43. Vaidya JS, Wenz F, Bulsara M, et al; TARGIT Trialists' Group. Risk-Adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383(9917):603-613.
44. Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): A randomised controlled equivalence trial. Lancet Oncol. 2013;14(13):1269-1277.
45. Rivera R, Banks A, Casillas-Lopez A, et al. Targeted intraoperative radiotherapy for the management of ductal carcinoma in situ of the breast. Breast J. 2016;22(1):63-74.
46. Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): A randomised, double-blind, phase 3 clinical trial. Lancet. 2016;387(10021):849-856.
47. Roberts MC, Wheeler SB, Reeder-Hayes K. Racial/ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: A systematic review. Am J Public Health. 2015;105 (suppl 3):e4-e15.
48. Flanagan MR, Rendi MH, Gadi VK, Calhoun KE, Gow KW, Javid SH. Adjuvant endocrine therapy in patients with ductal carcinoma in situ: A population-based retrospective analysis from 2005 to 2012 in the National Cancer Data Base. Ann Surg Oncol. 2015;22(10):3264-3272.
49. Shah C, Wobb J, Grills I, Wallace M, Mitchell C, Vicini FA. Use of intensity modulated radiation therapy to reduce acute and chronic toxicities of breast cancer patients treated with traditional and accelerated whole breast irradiation. Pract Radiat Oncol. 2012;2(4):e45-e51.
50. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: A systematic review and meta-Analysis. J Natl Cancer Inst. 2011;103(17):1299-1309.
51. Duffy SW, Dibden A, Michalopoulos D, et al. Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: A retrospective population-based study. Lancet Oncol. 2016;17(1):109-114.
52. Young SS, Karr A. Deming, data and observational studies. Significance. 2011;8(3):116-120. doi:10.1111/j.1740-9713.2011.00506.x.